Avadel Pharmaceuticals plc
AVDL
Market Cap$1.42B
Close$
$-0.50
103.2% downside
Current Fair Value
103.2% downsideOvervalued by 103.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.42 Billion |
|---|---|
| Enterprise Value | $1.40 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.51 |
| Beta | 1.47 |
| Outstanding Shares | 96,726,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -488.43 |
|---|---|
| PEG | 287.44 |
| Price to Sales | 7.88 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.33 |
| Enterprise Value to EBIT | 428.99 |
| Enterprise Value to Net Income | -479 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.42 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Avadel Pharmaceuticals plc
CEO: Gregory Divis